Genomics pioneer Prof. George Church of Harvard Medical School will chair INanoBio’s Scientific Advisory Board.
Sequencing a person’s genome can identify susceptibility to various diseases, aid in early disease diagnosis, and enable precision medicine – personalization of therapy based on individual specific genomic biomarkers.
Detecting diseases in early stages dramatically improves therapeutic outcomes. In Cancer, average 5 year survival rate is close to 90% when diagnosed at stage 1, and stands at less than 25% when diagnosed at stage 4. In contrast, cost of therapy when diagnosed post metastasis is approximately 2.5 times that when diagnosed at early stages.